SeaStar Medical Holding Corporation Cash Flow Conversion Efficiency
SeaStar Medical Holding Corporation cash flow conversion efficiency. Based on the latest financial reports, SeaStar Medical Holding Corporation (ICU) has a cash flow conversion efficiency ratio of -0.697x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.99 Million) by net assets ($4.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SeaStar Medical Holding Corporation (2020–2025)
Cash flow conversion efficiency of SeaStar Medical Holding Corporation from 2020 to 2025. This chart illustrates how SeaStar Medical Holding Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest SeaStar Medical Holding Corporation stock price today for real-time trading data and today's change.
SeaStar Medical Holding Corporation Cash Flow Conversion Ratio Explained
SeaStar Medical Holding Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SeaStar Medical Holding Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SeaStar Medical Holding Corporation ranked by their cash flow conversion efficiency. Also see SeaStar Medical Holding Corporation market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RE Royalties Ltd
V:RE
|
0.166x |
|
ESV Inc
KQ:223310
|
-0.403x |
|
Indonesian Tobacco Tbk PT
JK:ITIC
|
0.027x |
|
Bridgeline Digital Inc
NASDAQ:BLIN
|
-0.004x |
|
Magna Polonia SA
WAR:06N
|
-0.007x |
|
Greenvale Energy Ltd
AU:GRV
|
-0.058x |
|
SOLUTIANCE AG NA O.N.
F:SLSA
|
N/A |
|
Barfresh Food Group Inc
NASDAQ:BRFH
|
7.964x |
Annual Cash Flow Conversion Efficiency for SeaStar Medical Holding Corporation (2020–2025)
The table below shows the annual cash flow conversion efficiency of SeaStar Medical Holding Corporation from 2020 to 2025. Review ICU financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.42 Million | $-13.60 Million | -1.306x | -117.81% |
| 2024-12-31 | $-2.18 Million | $-16.01 Million | 7.333x | +888.85% |
| 2023-12-31 | $-13.87 Million | $-10.29 Million | 0.742x | +97.53% |
| 2022-12-31 | $-20.76 Million | $-7.79 Million | 0.375x | -79.33% |
| 2021-12-31 | $-2.82 Million | $-5.11 Million | 1.816x | +2233.07% |
| 2020-12-31 | $-71.58 Million | $-5.57 Million | 0.078x | -- |
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperi… Read more